Tagged with mRNA

Saudi Arabia Since joining Moderna as its first ex-US commercial employee in Spring 2020, Dan Staner has played a leading role in developing what is now one of the world’s top 20 biggest pharma companies. Speaking exclusively to PharmaBoardroom, Staner describes how Moderna has been able to fashion a new, optimised company…

Global The speed with which Pfizer-BioNTech and Moderna’s COVID-19 vaccines were brought forward may have made the mRNA technology behind them appear novel. In fact, the pioneers whose discoveries enabled the creation of these vaccines, recent Nobel prize winners Katalin Karikó and Drew Weissman, had been working on the mRNA and…

China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…

Global The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT US Pharma and Biotech Summit Sanofi’s CEO Paul Hudson demonstrated that the company is not just riding the current wave but continuing to innovate on…

China Despite rapidly developing and rolling out two vaccines against COVID-19 – from domestic firms Sinopharm and Sinovac – China is yet to approve a vaccine that uses mRNA technology, either from a domestic firm or one of the two international products (Pfizer/BioNTech and Moderna) currently approved elsewhere.   As the…

USA The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based company’s CEO Stephane Bancel remains unconcerned and believes that their successful vaccine is just the beginning of the mRNA era…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company.   We quickly recognized that the…